Amylin to adopt new sales approach for diabetes market
SAN DIEGO A company that worked with Eli Lilly & Co. to develop the diabetes drug Byetta (exenatide) announced Monday a plan to adopt a new sales approach to target the diabetes market.
Amylin Pharmaceuticals said its existing primary care and specialty sales forces will merge into a single organization to bring a specialty approach to endocrinologists and diabetes-focused primary care physicians. It said it expects to implement the changes in the next several weeks and reduce the total number of sales representatives by 200 employees.
“This new, more focused approach to sales optimizes Amylin’s sales organization for our portfolio today and in the future and will help us to improve the quality of our interactions with core prescribers through more efficient and frequent interactions,” Amylin president and CEO Daniel Bradbury said. “These changes build on Amylin’s scientific strength and leverage Lilly’s expertise and reach with primary care prescribers, so that we are well-positioned to address the information needs of the complex diabetes market.”
New details emerge on NACDS realignment
ALEXANDRIA, Va. The National Association of Chain Drug Stores Monday revealed further details of a sweeping management realignment and staff reduction. The announcement followed the organization’s first revelation on Thursday, April 30, that it was undertaking a streamlining and consolidation to shed operating costs in a difficult economy, and to respond more effectively to member needs in a shifting political and healthcare environment.
The overhaul includes the consolidation of some departments and a reduction of 15 filled full-time positions, from 92 to 77, or 16%.
Among the NACDS staff members leaving under the reorganization are Fitz Elder, VP of member relations and chief member relations officer; Phil Schneider, VP external relations and president of the NACDS Foundation; and membership coordinator Conchi Vallecillo. All three are taking voluntary retirement, NACDS revealed, and their positions “will not be refilled.”
A dozen other staff members are also headed for the exits, and their positions are being eliminated, according to the organization. They include Kate Crummett, manager of meetings and special events; senior graphic designer Kerrin Cuison; director of technology standards Michele Davidson; IT support specialist David Dorsey and Dan Faoro, VP communications production and strategic marketing.
Also leaving are Resource Center coordinator Marcy Gascoine; Ashley Matthews, coordinator of conference services and exhibits; membership coordinator Teresa Muldrow; Steve Poston, director of IT and facility services; web/database applications specialist Bikrum Saluja, director of policy and programs Christina Thompson; and Lisa White, manager of meetings and international affairs.
On Thursday, NACDS termed the staff cutbacks “very difficult” but necessary in the current economic downturn. The changes, noted the group, are “part of a comprehensive, multi-year plan to refocus and realign…activities and programs” to make NACDS more responsive to its members’ goals and current market realities.
In line with the streamlining effort, NACDS has grouped its 77-member team and its activities under six senior executives, all of who report to president and CEO Steven Anderson. They include:
- Finance and Accounting, human resources and administration and information services, headed by EVP and CFO Jim Huber;
- Membership, meetings and exhibits and international affairs, under the direction of Jim Whitman, SVP meetings and exhibits;
- Federal and state policy and programs, headed by Carol Kelly, SVP government affairs and public policy;
- Legal affairs, under SVP legal affairs and general counsel Don Bell;
- Pharmacy affairs, pharmacy education and the NACDS Foundation, headed by Edith Rosato, SVP pharmacy affairs;
- Media relations, member communications and Internet activities, under Chris Krese, SVP marketing, communications and media relations.
Antibiotic voluntarily recalled by Ranbaxy
PRINCETON, N.J. All supplies of an antibiotic will be recalled amid concerns that it could cause nausea and vomiting.
Ranbaxy Pharmaceuticals announced last week that it would voluntarily recall all lots of the drug Nitrofurantoin (monohydrate and macrocrystals) capsules in the 100-mg strength.
The company said some lots were defective, but decided to recall all lots as a precaution. The company, based in Gurgaon, India, said it is conducting the recall in coordination with the Food and Drug Administration at the retail level. Recalled lots of the drug are unlikely to produce serious adverse effects, Ranbaxy said, but a remote possibility exists of nausea and vomiting. The company said patients using the drug should consult their physicians about alternative medication options.